# Pyramid Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pyramid-biosciences

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.pyramidbio.com
- Total disclosed funding: $42M
- Latest round: Series B (Oct 1, 2021)
- Investors on record: 6

## About

Pyramid Biosciences Inc. is focused on developing innovative biopharmaceutical products to meet unmet medical needs across various therapeutic areas, utilizing advanced bioscience techniques for drug discovery and development.Founded in 2015, Pyramid Biosciences Inc. is based in Waltham, US, and specializes in biopharmaceutical product development. The company has conducted a total of 4 deals, with its most recent funding round being a Series B in October 2021, raising USD 33.54 mn led by Oracle Investment Management, Inc. The CEO is Brian Lestini, alongside Kollol Pal. The firm has not undergone any publicly reported strategic pivots or changes in its operational focus.Pyramid Biosciences specializes in developing biopharmaceutical products aimed at addressing unmet medical needs through a proprietary drug discovery platform. The company targets therapeutic areas such as oncology and metabolic disorders, enhancing patient outcomes and improving drug development efficiency. Their clientele includes research institutions and pharmaceutical companies across North America and Europe, facilitating both clinical and commercial drug development applications.Pyramid Biosciences generates revenue from direct partnerships with pharmaceutical companies and research organizations, primarily through B2B collaborations for its drug discovery platform. Revenue streams include milestone payments and royalties linked to successful product outcomes, with structured contracts that define clear deliverables tied to specific research phases. The pricing for these services reflects the complexity and customization needed for each project, ensuring alignment with client research objectives.Pyramid Biosciences Inc. intends to leverage its recent Series B funding of USD 33.54 mn, raised in October 2021, to accelerate the development of new biopharmaceutical products and expand into new geographic markets. The company aims to utilize its proprietary drug discovery platform to introduce innovative treatment options, particularly targeting oncology and metabolic disorders. Additionally, it plans to enhance its market presence in North America and Europe, aligning its strategic initiatives with client needs and research advancements.

## Funding rounds

- Series B, Oct 1, 2021, $34M — Adage Capital Management, Oracle Investment Management, Inc., J.W. Childs Asia Equities (Hong Kong), Montanova Capital
- Series A, Aug 7, 2020, $8.8M — Prospect Hill Growth Partners, Adage Capital Management, Suvretta Capital Management

## Investors

- Prospect Hill Growth Partners (https://capitalatlas.ai/funds/prospect-hill-growth-partners) — Series A
- Adage Capital Management — Series A, Series B
- Suvretta Capital Management — Series A
- Oracle Investment Management, Inc. — Series B
- J.W. Childs Asia Equities (Hong Kong) — Series B
- Montanova Capital (https://capitalatlas.ai/funds/montanova-capital) — Series B